Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong

Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors

San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million.

Campbell and CO Investment Adviser LLC bought a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,619 shares of the company's stock, valued at approximately $218,000. Other hedge funds

California-based TCG Crossover Management increased its stake in Centessa Pharmaceuticals by 245,664 shares in the third quarter for an estimated $38.1 million. The transaction value equaled about 0.2% of the fund's 13F reportable assets under management (AUM) at quarter-end.

It's gearing up to take in a flood of fresh capital. This is being effected in a secondary issue of its ADSes.

BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about November 14, 2025, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,744,186 ADSs at the public offering price, less underwriting discounts and commissions.

BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa.

BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Wednesday, November 12, 2025 Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare Conference in London Date: Tuesday, November 18, 2025 Fireside Chat: 2:00 PM GMT/ 9:00 AM ET Event: 37th Annual Piper Sandler Healthcare Conference Date: Tuesday, December 2, 2025 Fireside Chat: 3:00 PM ET Event: 8th Annual Evercore Healthcare Conference Date: Wednesday, December 3, 2025 Fireside Chat: 9:35 AM ET Event: Oppenheimer Movers in Rare Disease Summit Date: Thursday, December 11, 2025 Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients.

Y Intercept Hong Kong Ltd purchased a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 46,665 shares of the company's stock, valued at approximately $613,000.

BOSTON and LONDON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results for the third quarter ended September 30, 2025 and provided an update on its OX2R agonist program, including Phase 2a data1 from the initial dosing cohorts within the ongoing CRYSTAL-1 study of ORX750 in NT1, NT2 and IH participants, and Phase 1 data2 from the ongoing study of ORX142 in healthy volunteers.

BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

Centessa Pharmaceuticals (CNTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. ORX142 is the second drug candidate from the Company's multi-asset orexin franchise.